Progenics' (PGNX) Relistor Setback Only a Speedbump - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Needham & Company Defends Progenics (PGNX) on PDUFA Delay, Valeant Overhang
April 4, 2016 1:23 PM EDTNeedham & Company analyst Chad Messer has come out to defend Progenics Pharmaceuticals (NASDAQ: PGNX), which is down 6.5% after the FDA extended oral Relistor PDFUA by 3 months to July 19th. The FDA made the extension in order to review responses by Valeant to recent... More
Valeant Pharma (VRX), Progenics (PGNX) PDUFA for Oral RELISTOR Extended by 3 Months
April 4, 2016 7:03 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Oral... More
